Jeremy Ahouse, CSAP, PhD
Vice President, Alliances
Merus, N.V.

Merus (, a clinical-stage immuno-oncology company develops therapeutics with the goal of treating and curing serious illnesses. Merus' Multiclonics® therapeutics are produced from our proprietary technology platforms, which are able to generate a diverse array of antibody binding domains against virtually any target. Multiple binding domains can be combined to produce novel bispecific and trispecific antibodies, using our Biclonics® and Triclonics® platforms.

Jeremy is responsible for establishing Merus' alliance function and managing a broad research and clinical collaboration with current (e.g., Incyte, Lilly/Loxo, Simcere, Betta) and future partners. Jeremy has worked in pharmaceutical and biotech research and clinical collaborations with Celgene, Novartis, ImmunoGen, Vantage Partners, and Millennium.

Jeremy served on the board of the Association of Strategic Alliance Partners (ASAP) and helped to establish their CAAM and CSAP certification exams and contributed to the ASAP best practices guide. He serves on the leadership team of the NE ASAP chapter.

He earned his PhD in immunology and biophysics, and held an HHMI post-doc in Developmental Genetics. He trained as a mediator and negotiator at Harvard's Program on Negotiation and has a keen interest in multi-party agreements and in how working together helps research and drug development by improving how we come to do research and development together–the epistemology of collaboration.

Patrick Anquetil, PhD
Chief Executive Officer
Portal Instruments

Patrick Anquetil, Ph.D. is Portal Instrument's Chief Executive Officer. He brings more than 20 years of experience building world-class teams and leading high-tech / tough-tech bioengineering companies from the lab to the marketplace. Prior to founding Portal, he was co-founder of SynapDx, an autism diagnostic company based on RNA expression analysis, and Aretais, a venture in the field of blood glucose monitoring leveraging advances in Coherent Anti-stokes Raman Spectroscopy. Dr. Anquetil began his career as a science and nanotechnology equity research analyst at Susquehanna International Group authoring and marketing equity research reports to hedge funds and portfolio managers. Dr. Anquetil holds a doctorate in bio-instrumentation from MIT, an MBA from Harvard Business School, and a master's degree from the ETH in Zurich and the University of Tokyo. His scientific work has appeared in peer-reviewed publications as well as mainstream media, including MIT Technology Review, Wired Magazine, PBS, and CNBC.

Dr. Gideon Bosker
Co-founder & CEO

Gideon Bosker, MD, the co-founder and CEO of DarwinHealth™, brings to this "precision-focused" organization the knowledge, principles, and aspirations nurtured during his 15-year career as an academic scholar and clinician.

While a faculty member at the Yale University School of Medicine and Oregon Health Sciences University, Dr. Bosker authored and/or or edited multiple core textbooks and journals in clinical medicine and pharmacotherapeutics among them, Pharmatecture: Minimizing Medications to Maximize Results, The Manual of Emergency Medicine Therapeutics, Clinical Consensus Reports, The Textbook of Primary and Acute Care Medicine, The QuickConsult Manual of Primary Care Medicine, Geriatric Emergency Medicine, and Pills that Work, Pills that Don't.

Under his direction over the past 10 years, as Founder and CEO of CMEducation Resources, this globally-focused company has produced award-winning, live and digitally-based independent medical education programming in the fields of clinical oncology, biologics-based therapy, genomics-driven precision cancer medicine, diabetes, thrombosis, neurodegenerative disease, obesity, cardiovascular disease, medical diagnostics, genetic screening, and metabolic disorders. These multi-platform initiatives, deploying proprietary technologies and reaching tens of thousands of physicians worldwide, have been implemented under the sponsorship of leading biopharmaceutical and diagnostics companies, including Bayer Healthcare, Pfizer, Bristol Myers Squibb, Genentech, Roche, Daiichi Sankyo, Ipsen, Novo Nordisk, Astra Zeneca, Eisai, Sanofi, Regeneron, Amgen, Genzyme, Natera, Teva, and Quest.

His leadership roles at both DarwinHealth™ and CMEducation have been instrumental in galvanizing an international network of the world's leading scientists, clinical investigators, strategists, and industry leaders who share a commitment for advancing the frontiers and foundations of cancer medicine–as well as other critical disease states with unmet therapeutic needs–based on scientifically rigorous and innovative discoveries and technologies.

Christine A. Carberry, CSAP
Carberry Consulting

Christine Carberry is a biopharmaceutical leader with the unique ability to transform strategy into results through the power of collaboration. Most recently she was the Chief Operating Officer at Keryx Biopharmaceuticals. In her leadership role she served on the Executive Committee while leading initiatives in cross-functional integration, operational excellence, and program management. She headed the Manufacturing, Technical Operations, Quality, Human Resources, and Regulatory functions.

Prior to Keryx, she served as a Senior Vice President at Forum Pharmaceuticals. At Forum, She established the Program & Alliance Management cross-functional matrix to integrate across the entire organization. She also led the CMC, Supply Chain, and Quality functions.

At Biogen for over 25 years, Christine held positions of increasing responsibility as the company advanced from a biotechnology pioneer to an internationally recognized Fortune 500 company.

Christine is a Certified Strategic Alliance Professional (CSAP). She holds an M.S. in innovation and technology management from Boston University, Graduate Certificates in Management and Biotechnology Strategy from Harvard University, and a B.S. in biochemistry from the University of New Hampshire.

Fiona Chennells
ECMC Operations Lead
Cancer Research UK

Fiona is the Operations Lead for the Experimental Cancer Medicine Centre Network (ECMC), a UK network of 18 Adult and 11 Paediatric world leading clinical research centres, driving the discovery, development and testing of new treatments to combat cancer. Since 2017 Fiona has supported commercial and academic research organisations including Pharma, Bio, Medtech and CROs to engage with the ECMC network, conduct early phase oncology clinical trials and develop academic collaborations. Prior to her time with Cancer Research UK, Fiona spent 20 years with Roche Pharmaceuticals, latterly as Head of Data Management and Biometrics in the UK.

Leigh Cherry
Vice President, Strategic Business Support, Janssen Supply Chain
Janssen Pharmaceutical Companies of Johnson & Johnson

Leigh is the head of Janssen Supply Chain's Strategic Business Support organization leading the evaluation, negotiation, and execution of business development transactions on behalf of Janssen Supply Chain. Leigh is a leader within Janssen's Value Chain Management organization with responsibility for end-to-end supply chain oversight of products both commercial and in development.

With over 30 years of pharmaceutical supply chain experience, Leigh has held various roles leading manufacturing operations in biologics, vaccines, and small molecules, large molecule and medical device external manufacturing, value chain management, procurement, planning, business development, and alliance management. Leigh joined the Johnson & Johnson Family of Companies in 2016. Leigh previously worked at Merck & Co., Inc.

Leigh holds a Bachelor of Science degree in electrical engineering from Lafayette College and a Master of Business Administration from Harvard Business School.

Mark Coflin, CSAP
Vice President, Head Global Alliance Management
Simcere Pharmaceutical Group





John Glavas
Associate Vice President External Manufacturing and Strategy

John Glavas has over 25 years of operational experience in both Pharmaceutical and Biotechnology industries. John joined Merck as AVP Site Lead for Merck's Oss Biologics, Netherlands's manufacturing site in 2017 and as a member of the Global Biologics and Sterile Leadership Team. Currently John manages Merck's COVID response Program as part of the Merck Manufacturing Division.

Prior to joining Merck John was Vice-President and Site Director for GSK's Ste-Foy, Quebec vaccines manufacturing site from 2010 and was a member of the Canadian Country Management Board representing the Vaccines Manufacturing business. John oversaw and managed the manufacturing and supply of seasonal and pandemic influenza vaccine sourced from the Quebec site.

Prior to joining GSK, John worked as VP Manufacturing, Global Operations at PharmaScience Inc. He also held several roles at Draxis Pharma Inc. within Engineering, Production and finally as General Manager Non-Sterile Business Unit. During these 25 years in the pharmaceutical industry, he built a reputation as a strong leader with a proven track record in successfully delivering large scale, trans formative, projects for the businesses.

John has a bachelor's degree in chemical engineering and a master's degree in manufacturing management from McGill University.

Jessica Goodman, PhD, CA-AM
Senior Director of Alliance Management

Jessica Goodman, PhD, CA-AM, is currently the Senior Director of Alliance Management at Dicerna Pharmaceuticals where she is responsible for establishing and maintaining successful, value-generating R&D pharmaceutical alliances by supporting productive working relationships, removing non-scientific barriers, and identifying ways to minimize risk. Prior to joining Dicerna, Jessica led the Corporate Alliances team at Harvard's Office of Technology Development (OTD), where she used alliance and project management to maximize the value of early stage research alliances. Before OTD, Jessica held multiple alliance, project, and program management positions including at a small ALS non-profit, Prize4Life, and at Biogen. Jessica holds a PhD in Molecular Biophysics and Biochemistry from Yale University and was a NIH NRSA postdoctoral fellow at the Whitehead Institute.

Nancy Griffin, CA-AM
VP, Alliance Management
Dicerna Pharmaceuticals

Nancy Griffin is Vice President of Alliance Management at Dicerna Pharmaceuticals, Inc., responsible for alliance portfolio management for each of the company's discovery development collaborations, with a focus on building effective and constructive strategic alliances to exceed operational goals and demonstrate valuable differentiation. Prior to her role at Dicerna, Nancy held alliance leadership roles at Vertex Pharmaceuticals, Novartis AG, Novartis Oncology and Bayer Healthcare. With more than 20 years of international experience in the pharmaceutical sector, Ms. Griffin has worked across business development, licensing, business intelligence and drug development, including clinical operations, regulatory and clinical trial management.

Ms. Griffin is a board member of EcoHealth Alliance (EHA), a non-profit focused on scientific research and global alliances addressing pandemic prevention. She joined the EHA board in 2018 and, since then, has taken on additional responsibilities as Board Secretary and Chair of the Audit Committee.

Ms. Griffin has an undergraduate degree in Nursing Science from the University of Toronto, an MBA from Quinnipiac University and an MPH from George Washington University.

Katherine Kendrick, CSAP
Head of Alliance Management
Jazz Pharmaceuticals

Katherine Kendrick is Head of Alliance Management at Jazz Pharmaceuticals, a global biopharmaceutical company that develops life-changing medicines for people with serious diseases, who often have limited or no options. Katherine leads the Jazz Alliance Management team and department, delivering alliance portfolio management and value for global partnerships in development and commercial life cycle phases. Prior to joining Jazz in 2019, Katherine was with Eli Lilly & Company and Elanco Animal Health, where she established and led the Alliance Management organization. For more than 20 years, Katherine has focused on global clinical development and strategic alliance partnering in the human and animal health pharmaceutical sector. She is passionate about building and optimizing alliance teams and advising alliance leaders, enabling challenging decision-making with a patient focused, alliance value driven approach. Katherine holds a BS in Biomedical Science from Texas A&M University and has been an active member of ASAP since 2011. It's not all about work for Katherine–in her personal time, she is a veterinary nursing student at Purdue University and volunteers with the veterinary team for Save Elephant Foundation in Thailand, rescuing and rehabilitating endangered Asian Elephants.

Michael Leonetti, CSAP
President & CEO
Association of Strategic Alliance Professionals



Scott Mosier
Director of Alliance Management
Atara Biotherapeutics

As the Director of Alliance Management for Atara Biotherapeutics, Scott manages collaborations with leading academic research institutions and global industry partners. Atara's collaborations are focused on pioneering the development of transformative therapies for patients with serious diseases including solid tumors, hematologic cancers, and autoimmune diseases through the use of Atara's allogeneic EBV T-cell platform. In this role, Scott focuses on embedding good partnering practices throughout each collaboration as well as driving alignment, timely decision-making, and clear strategic program planning. Scott brings more than 10 years of biotech experience managing collaborations across a range of therapeutic areas including oncology, respiratory, and bone health.

Prior to joining Atara, Scott held multiple roles at Amgen in Alliance Management, Business Development, and Finance. Scott holds a BA in Political Science from UCLA and an MBA from the UCLA Anderson School of Management and is CA-AM certified.

Chandra Ramanathan, PhD
Global Head, Pharma R&D Open Innovation

Chandra Ramanathan, Global Head of Pharma R&D Open Innovation, leads the Open Innovation Centers (OICs) around the world (US, Europe, Japan, China and Singapore). The OICs focus on early access to breakthrough technologies, management of strategic alliances, and public private partnerships.

Chandra's previous roles at Bayer include Head of Open Innovation Center North America-East, Global Program Lead for External Innovation/Life Sciences, Global Launch Team Leader (copanlisib) and Head of Global Oncology Pipeline Marketing.

Prior to joining Bayer, Chandra worked at Wyeth (Pfizer) and Bristol-Myers Squibb in various roles in Drug Discovery, Applied Genomics, and Business Development & Licensing.

Chandra earned an MBA from the Columbia Business School, a PhD in Genomics/ Bioinformatics, an MS in Medicinal Chemistry, and a BS in Pharmacy.

Chandra is an adjunct assistant professor at the Tufts School of Medicine and is on the Board of Directors of MassBIO, the Massachusetts Biotech Council.

R. Lynn Richard, CSAP
Vice President, Chief Alliances Officer, Global and Strategic Alliances
GE Healthcare

Lynn Richard has more than 25 years of experience in technology and consulting roles serving government, telco, financial services, healthcare, and technology industries. Leveraging extensive experience in partner optimization and channel strategies, Lynn is expert in driving business expansion, creating alliances and partnerships which drive incremental revenue, business development and mergers and acquisitions.

R. Lynn Richard is presently Chief Alliances Officer and Vice President, Global and Strategic Alliances at General Electric Healthcare. Lynn is responsible for designing, leading, and driving strategy and execution with strategic alliances and partners, including both technology and pharmaceutical alliances. Lynn leads collaborations with some of the top technology, pharmaceutical and services companies in the world. Before joining GE Healthcare, Lynn was an alliance leader in Unisys Corporation and held several senior sales, marketing, and alliances leadership roles at IBM.

Lynn holds a Master of Business Administration, Marketing and Management from Murray State University and a Bachelor of Science in Political Science and Business Administration from Murray State University. He also received a Graduate Degree in Banking from University of Colorado where he won the Scholastic Achievement Award. He is a regular contributor to and presenter at Association of Strategic Alliance Professionals conferences and is a Certified Strategic Alliance Professional (CSAP). He presently serves as a Board of Directors Member of the Association of Strategic Alliance Professionals.

Louis Rinfret, PhD
Founder and CEO

Louis Rinfret is founder and CEO of allianceboard, the alliance management platform. Louis has over two decades of experience in the software industry moving from technical and product management roles to leading business units and strategy for organizations ranging from start-ups and research institutes to multi-nationals such as SAP Business Objects and Expedia CruiseShipCenters. Combining his passions for technology and alliance management, Louis is on a mission to empower alliance managers to succeed with their strategic alliances.

Louis has been active in managing, teaching about and researching strategic alliances for the past 15 years and has been a member of the Association of Strategic Alliance Professionals (ASAP) since 2005. Louis holds a PhD in Strategy from Lancaster University (UK) where he wrote a thesis on the performance of strategic alliances.

Louis is an avid trail runner and when he is not at his desk you will probably find him training for the next race with his wife and two daughters.

Michael Roch, CA-AM
Chief Commercial Officer

Michael Roch is the Chief Commercial Officer of allianceboard, the alliance management platform. Michael loves helping organizations succeed with their partnership-based business models and has been working alongside partnerships, alliances and joint ventures in the knowledge services, technology, power generation and real estate sectors for most of his career as a consultant, attorney and entrepreneur.

Prior to joining allianceboard as Louis' partner, he served as Co-CEO Europe of a 4,000-member platform-based ecosystem originated in Australia. Michael also was co-founder and CEO of a London-based management consulting firm focused on partnerships and global alliances; within nine years, the firm served market leaders in more than 40 countries.

Michael has been a member of the Association of Strategic Alliance Professionals since 2016 and holds ASAP's CAAM certification. He holds an MBA and Juris Doctor from the University of Denver (USA) and is currently working on his DBA on coopetition management at Grenoble École de Management (France).

Michael's passion are music, tennis and skiing; he's an active member of Lions International. He lives in Zurich, Switzerland, with his wife and their most recent adoption, a Chocolate Labrador.

Siru Sengul
ECMC Network Lead
Cancer Research UK

Siru Sengul has 10+ years UK and global experience in cancer research from discovery to clinical application. She obtained her PhD at the University of Cambridge, UK and was a visiting researcher at the Stanford University, US. After working in cancer research within the pharmaceutical industry and academic setting Dr Sengul joined Cancer Research UK (CRUK) - the world's leading charity dedicated to cancer research- to be involved in improving patient outcomes more widely and in charity settings. At CRUK she worked in several key strategic projects and is currently the Network Lead at the Experimental Cancer Medicine Centre (ECMC) Programme Office ECMC is a collaboration of world-leading scientists and clinicians who bring together expertise to drive the discovery, development and testing of new anti-cancer treatments and biomarkers in early phase studies and trials, to deliver real patient benefits.

Jeffrey C. Shuman CSAP, PhD
Principal, The Rhythm of Business
Professor Emeritus of Management, Bentley University

Jeff is an educator and trusted advisor to executives who are building, leading, and managing alliances and partner networks. His mix of operational, consulting, research and classroom experiences allow him to blend the theoretical with the practical, providing useful, easily implementable and repeatable advice.

At The Rhythm of Business he partners with global companies in multiple industries to advance their alliance and collaboration management capability. Consulting engagements focus on driving results through enabling all functions of the business to work effectively with their partners throughout the lifecycle. He works with senior executive teams to shape partnering strategy, enable operational and organization readiness, and implement overarching governance. Partnering professionals benefit from his ability to quickly diagnose underperforming alliances, and accelerate the path to profitability. Customized education and training bring alliance and collaboration skills to all who interact with partners.

Jeff has been a member of ASAP since 2002. He was involved on the teams that developed the Certificate of Achievement – Alliance Management (CA-AM) certification and the CSAP certification and contributed to The ASAP Handbook of Alliance Management. He frequently presents at ASAP and other organization's conferences and events. Together with business partner Jan Twombly, he has a rich history of developing and publishing strategic and practical thinking that advances the art and science of partnering and alliance management.

Ben Siddall
Vantage Partners

Ben Siddall is a Partner at Vantage Partners, where his practice focuses on helping companies build and execute strategies which involve collaboration. Ben works primarily in the biopharma, device, and healthcare sectors, with additional experience in the technology and professional services sectors.

Ben's projects include a blend of strategic analysis and supporting individual relationships. His work often includes defining partner ecosystems, conducting scenario planning and war-gaming, defining criteria and processes to support selection of partners, launching new collaborations, and helping organizations define and improve their capability to partner effectively. He works with both innovation and customer related collaborations, and regularly works with cross-industry partnerships.

Prior to joining Vantage, Ben worked as an economic consultant and a commercial litigator. Ben received his J.D. cum laude from Georgetown University Law Center and his B.A. magna cum laude in political science from Boston University.

Helen Torley
President, Chief Executive Officer and member of the Board of Directors

Dr. Torley brings extensive commercial and business experience as well as an extensive knowledge of the biotechnology industry. Dr. Torley joined Halozyme in January 2014 as President and Chief Executive Officer. Throughout her career, Dr. Torley has led several successful product launches, including Kyprolis®, Prolia®, Sensipar®, and Miacalcin®. Prior to joining Halozyme, Dr. Torley served as Executive Vice President and Chief Commercial Officer for Onyx Pharmaceuticals (Onyx) from August 2011 to December 2013. In this role she was responsible for the successful launch of Kyprolis in the US and led the development of Onyx's commercial capabilities in ex-U.S. markets and in particular, in Europe. She also oversaw the development and commercial collaboration with Bayer on Nexavar® and Stivarga®.

Prior to Onyx, Dr. Torley spent 10 years in management positions at Amgen Inc., most recently serving as Vice President and General Manager of the U.S. Bone Health Business Unit from 2009 to 2011 and the U.S. Nephrology Business Unit from 2003 to 2009. From 1997 to 2002, she held various senior management positions at Bristol-Myers Squibb, including Regional Vice President of Cardiovascular and Metabolic Sales and Head of Cardiovascular Global Marketing. She began her career at Sandoz/Novartis, where she ultimately served as Vice President of Medical Affairs, developing and conducting post-marketing clinical studies across all therapeutic areas, including oncology. Before joining the industry, Dr. Torley was in medical practice as a senior registrar in rheumatology at the Royal Infirmary in Glasgow, Scotland.

She received her Bachelor of Medicine and Bachelor of Surgery degrees (M.B. Ch.B.) from the University of Glasgow and is a Member of the Royal College of Physicians (M.R.C.P). Dr. Torley is a member of the board of directors for Quest Diagnostics. She is also a former member of the Health Section Governing Board of BIO, the Biotechnology Innovation Organization.

Jan Twombly, CSAP
The Rhythm of Business

Jan Twombly, Certified Strategic Alliance Professional (CSAP), is president of The Rhythm of Business, a consultancy and advisory firm with core expertise in partnering, strategic alliances, and collaboration. For more than 20 years, she has been developing and sharing thought leadership to enable more collaborative ways of working and to achieve success through partnering and alliances.

Jan is a trusted advisor to leaders in both industry and academia, helping to develop their organizations' ecosystem partnering and alliance strategies. She offers education and training services to build the mindset, skillset, and toolset needed to succeed. Her clients count on her to advise on establishing new alliances, develop alliance management process and procedures, and to step in when alliances are in trouble. Data-driven, contextual assessments of complex alliances provide deep insights that solve problems and drive measurable improvement.

Her current emphasis is on working with alliance professionals to reimagine how alliance management is implemented in an environment of increasing demand and digitizing its workflow and reporting.

Jan serves on the Board of Directors of the Association of Strategic Alliance Professionals (ASAP), overseeing their editorial and content strategy. She is a frequent contributor to Strategic Alliance Quarterly, regularly speaks on collaboration and partnering, and together with Jeff Shuman, CSAP, PhD authors The Partnering Guide blog and numerous whitepapers at

Tim Van Hauwermeiren
Co-founder & CEO

Tim Van Hauwermeiren co-founded argenx and has served as Chief Executive Officer since April 2008. He has been a member of the Board of Directors since July 2014.

Tim has more than 20 years of general management and business development experience across the life sciences and consumer goods sectors, including at Ablynx and Procter & Gamble. He holds a B.Sc. and M.Sc. in bioengineering from Ghent University and an Executive MBA from The Vlerick School of Management.

Tim serves on the Board of Directors of iTeos Pharmaceuticals and Aelin Therapeutics where he is Chairman.

Nisha Zaidi, PhD MSc
Executive Director, R&ED Alliances Strategy & Business Development
Bristol Myers Squibb

Nisha is an Executive Director in Research & Early Development Alliances at Bristol Myers Squibb, a global pharmaceutical company whose mission is to discover, develop and deliver innovative medicines that help patients prevail over serious diseases. Nisha serves as a strategic alliance leader responsible for building and optimizing relationships and driving decision-making to ensure long-term sustainability of the Bristol Myers Squibb pipeline through combined internal and external innovation. In her current role, Nisha focuses on maximizing the value of strategic global partnerships, leading company integrations, and mentoring and advising alliance leaders through the life cycle of an alliance, to uphold Bristol Myers Squibb as a partner of choice.

With more than 20 years in the industry, Nisha has worked across Business Development & Global Alliances, Medical Affairs, and Research and Development. Nisha started off her career at Sanofi as a scientist before moving into Medical Affairs. Later at Celgene, Nisha led U.S. drug launches as a Medical lead before joining Global Alliances.

Nisha holds an undergraduate degree from Rutgers University and a master's degree and PhD from the University of Medicine and Dentistry of New Jersey.